<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837328</url>
  </required_header>
  <id_info>
    <org_study_id>UMN 1605M87323</org_study_id>
    <nct_id>NCT02837328</nct_id>
  </id_info>
  <brief_title>Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias</brief_title>
  <official_title>Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this research is to determine whether oral magnesium supplementation
      in healthy, community-living individuals will be associated with reductions in the burden of
      arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the primary objective, the Investigator will conduct a double-blind randomized
      trial assigning participants to receive 400 mg of oral magnesium in the form of magnesium
      citrate once daily or placebo. The investigators will recruit 60 individuals 55 years of age
      and older without a prior history of cardiovascular disease. At baseline, participants will
      undergo a basic examination, answer questionnaires and provide a blood sample to determine
      circulating magnesium levels. Participants will then wear an FDA-approved heart rhythm
      monitor (Zio Â® XT Patch) for 2 weeks. At the end of 2 weeks they will begin taking their
      assigned treatment (magnesium or placebo), and will continue doing so for a total of 12 weeks
      (through study week 14). After 10 weeks of taking the supplement or placebo (study week 12),
      they will have a final study visit in which the participants will provide another blood
      sample for assessment of circulating magnesium, and will be asked to wear the heart rhythm
      monitor for another 2 weeks (through study week 14). The primary endpoint will be the change
      in burden of premature atrial contractions (PACs), measured in episodes per day, between
      baseline and final follow-up visit. A secondary outcome will be the change in circulating
      magnesium between both exams.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">September 15, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Premature Atrial Contractions (PACs)</measure>
    <time_frame>Change from Baseline at 4 weeks</time_frame>
    <description>The primary endpoint will be the change in burden of PACs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Magnesium concentration</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The secondary endpoint will be the change in circulating magnesium between baseline and a follow-up visit 12 weeks later.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Premature Atrial Contraction</condition>
  <arm_group>
    <arm_group_label>Oral Magnesium Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Magnesium Citrate 1x daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Magnesium Supplement</intervention_name>
    <description>400 mg Magnesium Citrate 1x daily for 12 weeks</description>
    <arm_group_label>Oral Magnesium Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 55 and older

          -  Ability to speak English

          -  Availability to attend baseline and follow-up visit approximately 12 weeks after
             baseline

        Exclusion Criteria:

          -  Prior history of heart disease (coronary heart disease, heart failure, atrial
             fibrillation), stroke, severe renal disease

          -  Use of type I and III antiarrhythmics or digoxin

          -  Current use of magnesium supplements

          -  Any prior history of allergy or intolerance to magnesium

          -  Prior history of inflammatory bowel disease or any severe gastrointestinal disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela L Lutsey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, MN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvaro Alonso, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, MN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Y Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota, MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota - Twin Cities</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnesium Supplementation</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Dietary Supplement</keyword>
  <keyword>Arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Premature Complexes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

